FDA Dental Panel Will Consider BioMimetic PMA For Periodontal Diseases July 13
This article was originally published in The Pink Sheet Daily
Executive Summary
Sankyo Pharmaceuticals unit Luitpold has exclusive rights to distribute GEM 21S dental osseous defect therapy. BioMimetic expects European approval in the first half of 2005.